Introduction
Studies from the 1990s provide evidence that statins (HMGCoA reductase inhibitors) reduce the risk of stroke in patients with coronary heart disease (CHD) and in patients at high risk of cardiovascular disease [1] [2] [3] . In 2002, results from The Heart Protection Study showed that statin treatment for patients with a previous stroke reduce the risk of subsequent major vascular events [4] . The SPARCL study concludes that statins also reduce the overall incidence of strokes and of cardiovascular events in patients with a recent stroke or transient ischaemic attack (TIA) without previous CHD [5] .
A meta-analysis shows no evidence of differences in treatment effects across patient groups [6] . An updated Cochrane Review, first published in 2002, recommends that all ischaemic stroke or TIA patients should receive statins [7] . The Swedish national stroke guidelines also recommend secondary preventive treatment with statins in ischaemic stroke patients, irrespective of risk-factor level [8] .
The objective of health care in Sweden is, according to the Swedish Health and Medical Services Act of 1982, to provide good health and good care on equal terms to the whole population [9] . Generally, both health and health care in Sweden are good, but data still show health and health-care related differences between different groups in society [10] .
Socioeconomic status, often indicated by measures of income, education and occupation, is often used to measure an individual's social position in society. Ethnicity is also a source of status ranking. There is a structure of socioeconomic inequality in society which is strongly related to health, disease and death [11, 12] . This relation between socioeconomic status and health has been proven not only for the poorest patients, but a social gradient in health has also been demonstrated [13] . Two studies from Sweden show a higher stroke incidence and stroke mortality in patients with lower socioeconomic status [14, 15] . The health of populations has been more strongly affected by social and economic welfare than by health care. Still, resources for health care have shown to vary inversely with need, which is sometimes referred to as the inverse care law [16] .
In this study, data from Riks-Stroke, the Swedish Stroke Register, and data from Statistics Sweden are used to explore how statin treatment after stroke has disseminated and been implemented in Swedish stroke care. The main hypothesis is that there are differences in the prescribing of statins at discharge from hospital between patient groups (age, sex, socioeconomic status and country of birth) and that the rate at which statin prescribing after stroke has been implemented varies between patient groups.
Materials and methods
This hospital-based study includes patients registered in Riks-Stroke [17] . Riks-Stroke was established in 1994, and it covers all hospitals in Sweden admitting patients with acute stroke since 1998. Basic patient characteristics, stroke risk factors and outcome variables, including drugs prescribed at discharge for secondary prevention, have been recorded in the register by all hospitals admitting acute stroke patients. The coverage of the register was, during the study period, estimated to be approximately 85 % [18] .
Data from Riks-Stroke has, through the personal identification number, been merged with data from the Longitudinal Integration Database for Health Insurance and Labour Market Studies (LISA), Statistics Sweden, in order to retrieve individualised information on patients' highest level of education, income and country of birth [19] .
Patient selection
Included in this study were adult patients aged ≥18 years, who had had an ischaemic stroke (ICD-10-CM I63) between 1 April 2004 and 31 December 2009 and who were registered in Riks-Stroke (statin treatment after stroke has been registered in the same way since 1 April 2004).
Variable definitions
The main outcome variable was the prescribing of statins at discharge from hospital, measured as the proportion of patients with a statin prescription registered in RiksStroke. Patients' highest level of education and disposable income, taken from the LISA database, were used as indicators of socioeconomic status. Education was grouped into primary school (up to 9 years in compulsory school) (reference category), secondary school (the upper levels of comprehensive school) or university level. Disposable income was individualised from family income, registered for the calendar year before the year of the stroke, and recalculated using the Consumer Price Index for 2009. Income was grouped into tertiles: low income (reference category), medium income and high income.
Country of birth was grouped into Sweden (reference category), Nordic countries (excepting Sweden), Europe (excepting the Nordic countries) and other countries.
The age groups used were 18-59 (reference category), 60-69, 70-79 and 80+ years. Level of consciousness was categorised as 'Alert' (reference category), 'Drowsy' and 'Unconscious'. Variables for dependency in activities of daily living (ADL), smoking, history of stroke, atrial fibrillation, history of diabetes and antihypertensive medication at the onset of stroke were categorised as either 'Yes' or 'No', with 'No' as reference category.
The project was approved by the Ethical Review Board at Umeå University.
Statistical analyses
The proportion of patients who received statin treatment after stroke have been presented for groups defined by year of stroke onset, age group, sex, socioeconomic status and country of birth. Age-adjusted logistic regression was used for group comparisons. Age was included as a categorical variable (age groups), and the results have been presented as odds ratios (OR) with 95 % confidence intervals (CI).
Multiple logistic regression was used to simultaneously test the effect of several factors on the probability of receiving statin treatment. Tested factors were selected based on expected clinical relevance. Variables included from the stroke register were age, sex, smoking, ADL-dependency, history of stroke, atrial fibrillation, history of diabetes, antihypertensive medication at onset of stroke and level of consciousness on admission. For variables with more than 10 % missing values, a 'missing' category was included in logistic regression models, but OR were not presented in the results.
The rate at which statin treatment was implemented in different groups has mainly been presented graphically by plotting the change in proportion over time. In addition, the two-way interaction terms (year-by-age-group, year-by-sex, year-by-education, year-by-income, year-by-country-ofbirth) were included in the multivariable model to test if there was a difference in the rate of dissemination.
Statistical analyses were performed using SPSS ver. 19.0.0.1 (SPSS, Chicago, IL). The age groups with the largest and smallest proportion of statin prescriptions were those comprising patients aged 60-69 years (67.1 %) and 80+ years (27.2 %), respectively (OR 1.26, 95 % CI 1.20-1.33 and OR 0.35, 95 % CI 0.33-0.37, respectively) ( Table 1) . Patients aged 70-79 years had the highest increase in statin prescriptions over time compared with patients aged 18-59 years (p<0.001) (Fig. 1 ). Since the level of statin prescribing was so much lower in the age group 80+ years, Figs. 2-5 have been separated into two panels, i.e. patients aged 18-79 years and patients aged 80+ years, respectively.
Results

From
More men than women were prescribed statins (52.1 vs. 40.5 %; OR 0.88, 95 % CI 0.85-0.90) ( Table 1 ). The relative difference in statin prescribing between men and women decreased over time (p00.038), although the absolute difference remained at a similar level (Fig. 2) .
Socioeconomic status
A larger proportion of patients with a high level of education were prescribed statins (Table 1) . Among patients with a university education, secondary school education and primary school education, 57.3, 55.7 and 48.0 % received a statin. The adjusted odds were slightly higher for patients with secondary or university education (OR 1.07, 95 % CI 1.04-1.11 and OR 1.05, 95 % CI 1.01-1.10, respectively) compared with those with a primary school education, but the difference in prescribing behavior between secondary school education and primary school decreased over time (p00.032) (Fig. 3 ). More patients (56.6 %) in the highest income tertile were prescribed statins compared with patients with the lowest income (40.1 %) (OR 1.24, 95 % CI 1.19-1.28), but there was no difference between low and medium income (OR 1.02, 95 % CI 0.99-1.06) ( Table 1) . No interactions over time were found for income (p00.343) (Fig. 4) .
Country of birth
Data showed different proportions of statin use after stroke when patients' country of birth was considered. The lowest and highest proportions of statin prescribing were found for patients born in Sweden (45.6 %) and those born in Europe (54.9 %), respectively (Table 1) . When patient-related factors were adjusted for, the odds of statin prescription were higher when born in the Nordic countries (OR 1.07, 95 % CI 1.01-1.14), Europe (OR 1.31, 95 % CI 1.22-1.40) and countries outside of Europe (OR 1.20, 95 % CI 1.08-1.34) compared with Sweden. Prescribing to patients born outside of Europe increased more over time compared with prescribing to patients born in Sweden (p00.004) (Fig. 5) .
The exclusion of individual risk factors (history of stroke, smoking, atrial fibrillation, diabetes, antihypertensive medication) in the multivariable logistic regression had no substantial effect on the OR of the remaining variables (data not presented).
Missing data
For the main outcome, i.e., the prescribing of statins to patients being discharged from hospital, 0.9 % of patients had missing data. The variables with the highest proportion of missing data were education (15.2 %) and smoking (10.0 %). For all other variables, the highest proportion of missing data was 1.3 % (antihypertensive treatment).
Discussion
This analysis of data from more than 100,000 Swedish stroke patients showed that prescribing of statins after stroke has increased in all of the patient groups in the study from 2004 to 2009. Patients older than 80 years were less likely to receive statins for secondary prevention than those in the other age groups, a finding that has been reported in other studies [20, 21] . In the national guidelines, there is no upper age limit for patients to be prescribed statins after stroke, although discussions have taken place on the benefits and risks, cost-effectiveness and problems with polypharmacy in the highest age groups [22] . Scientific data on stroke prevention with statins for patients aged >80 years was limited at the beginning of the study period because of the exclusion or under-representation of this patient group in most clinical trials. Authors of more recent reviews, however, conclude that although the evidence is stronger for secondary prevention with statins after CHD than after stroke, the recommendation of statin treatment after ischaemic stroke should be applied also to the very elderly [23, 24] . Our data show that the proportion of patients receiving prescriptions for statins in the 80+ group steadily increased from 2004 to 2009. The differences between men and women are known from prior studies using the data from this register [25] [26] [27] . The difference persisted after controlling for the fact the women were, on average, 4.4 years older when they suffered a stroke. However, our study also showed that differences in statin prescribing between men and women decreased over time.
Both higher education and higher income were associated with a higher prescribing of statins, indicating more statins were given to patients with a higher socioeconomic status. A Swedish study on drugs bought by patients with a myocardial infarction (MI) also showed a slightly higher use of statins in patients with the highest level of education compared to those with the lowest level of education [28] . Another Swedish study on MI showed that a larger proportion of high-income patients collected lipid-lowering drugs from pharmacies after being discharged from hospital compared with low-income patients [29] . Socioeconomic differences are not unique to Swedish stroke care. In an international review, the evidence for such differences is strongest for mortality and incidence of stroke, but there is also evidence for outcome and stroke severity [30] . Differences in risk factors and, accordingly, the prevention of risk factors are likely to be part of a complex mechanism for socioeconomic differences in stroke. Variables used as indicators of socioeconomic status are often based on income, education and occupation. The use of occupation seemed to be less appropriate in this case since the majority of stroke patients would be classified as retired. There is often a correlation between different indicators of socioeconomic status. In our case we controlled for both education and income and then tested the correlation between education and income (Spearman's Rho); the results showed a low correlation (r00.091, p<0.001).
As previously mentioned, a Swedish study on patients with MI showed lower levels of statin use in patients born outside Sweden [28] . This is contrary to our findings in stroke patients. The study on MI is, however, based on sales data, and our study is based on prescription data. There may be differences between patient groups based not only on which drugs are prescribed, but also on which drugs patients decide to purchase. Even though statins in Sweden are subsidised and included in the high-cost-threshold, they are not for free (Swedish citizens pay a total maximum equivalent to 260 euro per 12-month period for subsidised drugs). Therefore, the affordability of the prescription is more likely to be a relevant issue when the focus is on whether patients do not purchase drugs versus whether drugs are prescribed. In our study, the focus was on prescribing drugs as a first step in how treatment is implemented. The main outcome variable was the prescribing of statins at discharge from hospital. Whether patients actually purchase and use their prescribed drugs is an important area of research but beyond the scope of this study.
Differences in prescribing have, in some cases, been shown to relate to patients' expectations, but also to prescribers' perceptions of patients' expectations [31] . The prescribing of drugs has also been correlated with patients' tendencies to seek health care [32] . Both patients' expectations of receiving a prescription and patients' tendencies to seek health care might vary between patient groups, but we were unable to analyse these areas with the available data. In our study, all patients were, however, treated in a hospital. Age distribution and the risk-factor profile were found to differ between different ethnic groups, with those patients born in Sweden being older and having more risk factors (data not shown), but the differences in the prescribing of statins remained even after adjusting for this difference. To fully understand the reasons for the ethnic differences seen in this study, future studies with more targeted data collection are needed.
This study provides real-life data on statin prescribing, and it includes data on approximately 85 % of all stroke patients in Sweden. Patients have been included from all hospitals that treated acute stroke patients. A previous analysis of data quality in Riks-Stroke showed high validity for the clinical data [17] . In many studies on differences in the use of drugs, aggregated data have been used as indicators of socioeconomic status, such as data at regional or health service levels [33, 34] . In this study, the association between the use of statins and socioeconomic status has been analysed on an individual level.
A national study of this size has high power to detect small differences; hence, clinical relevance has to be considered in addition to statistical significance. However, this study shows results with clinical implications. For example, the chance of being prescribed statins after stroke is one in three if you are older than 80 years. If you belong to a high-income group, you have a 25 % increased chance of receiving statins. To be able to assure a good and equal stroke care for all stroke patients, the differences have to be identified.
Health has been shown to be unequally distributed in society. Living conditions, environmental conditions as well as structures in society all affect public health. As long as there are differences in society there will be differences in health, and health care cannot solve this problem, but it should not increase the disparities. The National Guidelines for Stroke Care are based on horizontal equality: equal cases should be treated equally. However, the data in this study show lower levels of prescribing in groups with lower incomes and lower levels of education, groups that in studies have shown higher stroke incidence and stroke mortality. Treating everyone exactly the same, irrespective of, for example, risk level, does not necessarily yield equity, but groups with higher risks should not receive less preventive treatment.
Study limitations
Our study has a number of limitations. First, this is an analysis of prescribing patterns and not of which drugs are actually used by the patients. Patients might not start a treatment that has been prescribed or they might end a prescribed treatment. Differences in adherence to treatment between different patient groups could generate differences in the actual use of statins which are not equal to the differences in prescribing. Second, whether or not a patient is prescribed preventive drugs has been shown to be related to the practice of individual prescribers [35] . Including prescribers in this analysis was not possible since the stroke register does not include data on prescribers. Third, data quality in Riks-Stroke is continuously validated and has been shown to be high. However, those patients for whom some data were missing were more often elderly and affected by more severe strokes, which could have had impact on the results in this study. Lastly, the analysis controlled for several factors, including some patient characteristics and risk factors. One risk factor not included was a measurement of blood lipids. Data on cardiovascular comorbidities, such as previous MI, were not available.
Summary/conclusion
Statin prescribing after ischaemic stroke increased in Sweden between 2004 and 2009. Our results also show a social stratification in the dissemination of statins. Patients with higher incomes and higher levels of education were more frequently prescribed statins than those with a low income and those with a low level of education, and patients born in Sweden were prescribed statins less frequently than patients born in other countries.
